Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype

NCT04470726 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Superficial Basal Cell Carcinoma
Nodular Basal Cell Carcinoma
Nonmelanoma Skin Cancers

Interventions

DRUG: AIV001
DRUG: AIV001 suspension

Sponsor

AiViva BioPharma, Inc.